Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 6/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31296543 | 1.00 | IKBKB (0.35) | IKBKBCHUKCCR4CCR5TSHR | |
| SCHEMBL19071859 | 0.75 | IKBKB (0.38) | IKBKBCHUKTSHR | |
| SCHEMBL2178361 | 0.74 | MAPK1 (0.31) | — | |
| SCHEMBL1673946 | 0.73 | USP2 (0.32) | — | |
| SCHEMBL31696345 | 0.73 | USP2 (0.32) | — | |
| SCHEMBL6335472 | 0.72 | HRH3 (0.39) | — | |
| SCHEMBL558075 | 0.69 | HSD17B10 (0.34) | — | |
| SCHEMBL2310243 | 0.69 | MAPK1 (0.32) | — | |
| SCHEMBL31167898 | 0.69 | HSD17B10 (0.34) | — | |
| SCHEMBL17249992 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3814345-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3814345-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | IKBKB 1820/4885CHUK 1101/4885CCR4 4850/4885 |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | IKBKB 1820/4885CHUK 1101/4885CCR4 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.